PF-3758309 PF-03758309|cas:898044-15-0|西域试剂

PF-3758309 PF-03758309,99.84%

产品编号：Bellancom-13007| CAS NO：898044-15-0| 分子式：C₂₅H₃₀N₈OS| 分子量：490.62

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-13007	￥494.00	杭州北京（现货）
Bellancom-13007	￥790.00	杭州北京（现货）
Bellancom-13007	￥2350.00	杭州北京（现货）
Bellancom-13007	￥4400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PF-3758309 PF-03758309

产品介绍

PF-3758309 (PF-03758309) 是一种有效的、口服的、可逆的 ATP 竞争性 PAK4 抑制剂 (K_d= 2.7 nM; K_i=18.7 nM)。PF-3758309 具有 PAK4 抑制剂的预期细胞功能：抑制锚定独立生长、诱导凋亡、细胞骨架重塑和抑制增殖。

生物活性

PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (K_d= 2.7 nM; K_i=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation.

体外研究

PF-3758309 has similar enzymatic potency against the kinase domains of the other group B PAKs (PAK5, K_i=18.1 nM; PAK6, K_i=17.1 nM) and group A PAK1 (K_i=13.7 nM), but is less active against the other two group A PAKs (PAK2, IC₅₀=190 nM; PAK3, IC₅₀=99 nM).
In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC₅₀=1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC₅₀=4.7 nM).
PF-3758309 also inhibits endogenous pGEF-H1 accumulation in HCT116 cells. PF-3758309 potently inhibits cellular proliferation (IC₅₀=20 nM) and anchorage-independent growth (IC₅₀=27 nM) of A549 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

PF-3758309 (7.5-30 mg/kg; p.o.; twice daily for 9-18 days) results in statistically significant tumor growth inhibition (TGI) in HCT116 and A549 models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nu/nu, CRL breed 6–8 weeks old mice (bearing HCT116 and A549 tumors)
Dosage:	7.5-30 mg/kg
Administration:	Oral administration; twice daily for 9-18 days
Result:	Significant tumor growth inhibition (TGI) in HCT116 and A549 models.

体内研究

PF-3758309 (7.5-30 mg/kg; p.o.; twice daily for 9-18 days) results in statistically significant tumor growth inhibition (TGI) in HCT116 and A549 models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nu/nu, CRL breed 6–8 weeks old mice (bearing HCT116 and A549 tumors)
Dosage:	7.5-30 mg/kg
Administration:	Oral administration; twice daily for 9-18 days
Result:	Significant tumor growth inhibition (TGI) in HCT116 and A549 models.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (203.82 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0382 mL	10.1912 mL	20.3824 mL
5 mM	0.4076 mL	2.0382 mL	4.0765 mL
10 mM	0.2038 mL	1.0191 mL	2.0382 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (5.10 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.10 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (5.10 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.10 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.10 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.10 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。